<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Functional dyspepsia in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Functional dyspepsia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Functional dyspepsia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George F Longstreth, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian E Lacy, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4037982567"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dyspepsia is a common symptom with an extensive differential diagnosis and a heterogeneous pathophysiology [<a href="#rid1">1</a>]. The prevalence of uninvestigated dyspepsia worldwide is up to 20 percent, especially in females, smokers, and people taking nonsteroidal antiinflammatory agents. The prevalence varies according to the definition used for dyspepsia [<a href="#rid2">2,3</a>]. Dyspepsia can significantly impair quality of life [<a href="#rid4">4</a>]. The proportion of affected people who seek medical care ranges from 14 to 66 percent in various countries and ethnic groups [<a href="#rid5">5</a>]. The majority of patients (75 to 80 percent) with symptoms of dyspepsia are eventually categorized as having functional (idiopathic, nonulcer) dyspepsia. Many authorities regard it as a "disorder of gut-brain interaction" along with irritable bowel syndrome and other symptom-based gastrointestinal disorders [<a href="#rid6">6</a>], but the term "functional" is still commonly used. This topic review will provide an overview of the pathophysiology and treatment of functional dyspepsia. </p><p>Our recommendations for the diagnosis and management of functional dyspepsia are largely consistent with the American College of Gastroenterology, Canadian Gastroenterological Association, and American Gastroenterological Association guidelines [<a href="#rid7">7,8</a>], and a European expert consensus [<a href="#rid9">9</a>]. The etiology, general approach to the evaluation, and management of the patient with uninvestigated dyspepsia are presented separately. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia"</a>.)</p><p class="headingAnchor" id="H1788386988"><span class="h1">EPIDEMIOLOGY AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of functional dyspepsia ranges from 5 to 11 percent worldwide [<a href="#rid2">2,3</a>]. The pathophysiology of functional dyspepsia is not well understood. However, several potential mechanisms have been suggested. These mechanisms may differ between subtypes of functional dyspepsia (postprandial distress syndrome and epigastric pain syndrome) [<a href="#rid10">10</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastric emptying, accommodation, and vagal function </strong>– Functional dyspepsia has been associated with several motility disorders. These include mild delays in gastric emptying, rapid gastric emptying, antral hypomotility, gastric dysrhythmias, impaired gastric accommodation in response to a meal, and abdominal vagal dysfunction [<a href="#rid10">10-13</a>]. However, these findings vary among patients. (See  <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral</strong> <strong>hypersensitivity</strong> – Visceral hypersensitivity is characterized by a lowered threshold for induction of pain in the presence of normal gastric compliance. Visceral hypersensitivity independent of delayed gastric emptying has been demonstrated in patients with functional dyspepsia [<a href="#rid14">14</a>]. Both mechanoreceptor dysfunction and aberrant processing of afferent input in the spinal cord or brain may play a role in the pathophysiology of visceral hypersensitivity [<a href="#rid15">15</a>]. In one study that included 270 patients with functional dyspepsia, 37 percent had hypersensitivity to gastric distension, and hypersensitive patients reported higher cumulative symptom scores as compared with normosensitive patients [<a href="#rid10">10</a>]. Intraduodenal infusion of dextrose and lipids was also associated with symptoms in patients with functional dyspepsia, and an association of hypersensitivity with higher plasma concentrations of enteral hormones suggested hormonal mediation of the sensitivity [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Helicobacter</em></strong><em> </em><strong><em>pylori</em></strong> <strong>infection</strong> – The role of <em>H. pylori</em> infection in the pathogenesis of functional dyspepsia remains unclear (see  <a class="medical medical_review" href="/z/d/html/15.html" rel="external">"Pathophysiology of and immune response to Helicobacter pylori infection"</a>). Furthermore, only a small minority of patients with functional dyspepsia report symptom improvement after eradication therapy for <em>H.</em> <em>pylori</em> [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered gut microbiome</strong> – Alterations in the upper gastrointestinal tract microbiome may result in the development of dyspepsia. This hypothesis is supported by the observation that dyspeptic symptoms are more likely to occur after an episode of gastroenteritis [<a href="#rid18">18-21</a>]. In one study, risk factors for the persistence of dyspepsia eight years after exposure to a waterborne outbreak of bacterial dysentery were female sex, smoking, premorbid irritable bowel syndrome (IBS), anxiety, depression, and &gt;7 days of diarrhea or abdominal cramps during the acute illness [<a href="#rid19">19</a>]. It has been hypothesized that the efficacy of <em>H. pylori </em>therapy in improving symptoms of functional dyspepsia in some patients is due to the impact on the gut microbiome rather than the eradication of <em>H. pylori</em> alone [<a href="#rid22">22,23</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duodenal inflammation and immune activation </strong>– Increased eosinophils and mast cells and altered lymphocyte populations, including "gut-homing" lymphocytes, have been reported in the duodenum of patients with functional dyspepsia [<a href="#rid24">24-28</a>]. Structural and functional differences in duodenal submucosal ganglia between patients with functional dyspepsia and controls have also been described [<a href="#rid29">29</a>]. Confocal endomicroscopy has revealed increased epithelial gaps in patients with functional dyspepsia plus reduced transepithelial electrical resistance that was inversely correlated with symptom severity [<a href="#rid30">30</a>]. The proton pump inhibitor <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a> reduced duodenal eosinophils, mast cells, mucosal permeability, and symptoms in patients with functional dyspepsia [<a href="#rid31">31</a>]. These findings support the suggestion that luminal factors, such as acid and bile acids, cause low-grade inflammation that impairs mucosal integrity, resulting in abnormal gastrointestinal neuroregulation and symptoms [<a href="#rid32">32</a>].<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The hypothalamic-pituitary-adrenal (HPA) axis and stress </strong>– Patients with functional gastrointestinal disorders who experience mental stress can have increased activation of the amygdala and dysregulation of the HPA axis [<a href="#rid33">33</a>]. In healthy subjects, acute stress increases salivary cortisol levels and intestinal permeability [<a href="#rid34">34</a>]. In patients with functional dyspepsia, especially those with the epigastric pain subtype, magnetic resonance imaging of the brain revealed functional abnormalities in areas that process afferent signals [<a href="#rid35">35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial</strong> <strong>dysfunction</strong> – Functional dyspepsia has been associated with generalized anxiety disorder, somatization, and major depression [<a href="#rid36">36-38</a>]. There is also a higher prevalence of functional gastrointestinal disorders in patients with a self-reported history of childhood abuse [<a href="#rid39">39-41</a>]. In patients with the prototypical functional gastrointestinal disorder, IBS, a history of adverse early life events was related to HPA hyper-responsiveness to a visceral stressor [<a href="#rid42">42</a>]. A long-term follow-up study revealed initial trait anxiety was independently correlated with symptoms and quality of life; depression, anxiety, and comorbid functional somatic symptoms (IBS and chronic fatigue) were cross-sectionally associated with dyspepsia symptoms at follow-up [<a href="#rid43">43</a>]. The importance of psychosocial factors is further evident from an analysis of a large number of patients with functional dyspepsia that assessed gastrointestinal symptoms, psychological comorbidity, and extra-intestinal symptoms. The subjects clustered into four groups, two of which were characterized by high psychological burden [<a href="#rid44">44</a>]. </p><p></p><p class="headingAnchor" id="H4244969612"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with functional dyspepsia usually describe postprandial fullness, early satiety, bloating and/or epigastric pain/burning. Postprandial fullness is the most intense symptom in patients with meal-induced symptoms [<a href="#rid45">45</a>]. Symptoms may be severe enough to limit usual activities. Some patients may have nausea, vomiting, or heartburn, however, these symptoms are usually infrequent. </p><p class="headingAnchor" id="H1341666192"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2617472253"><span class="h2">Overview of diagnostic approach</span><span class="headingEndMark"> — </span>Functional dyspepsia is suspected in patients with a clinical history of postprandial fullness, early satiety, or epigastric pain/burning. A clinical diagnosis of functional dyspepsia requires the fulfillment of symptom-based diagnostic criteria and an evaluation to exclude other causes of dyspepsia. This evaluation consists of a history (eg, dietary, medical, surgical, family, and medications/supplements), physical examination, laboratory studies, and endoscopic evaluation to exclude organic/structural disease to explain the symptoms  (<a class="graphic graphic_algorithm graphicRef115195" href="/z/d/graphic/115195.html" rel="external">algorithm 1</a>). An approach to the evaluation of a patient with dyspepsia is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia", section on 'Initial evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia", section on 'Diagnostic strategies and initial management'</a>.)</p><p class="headingAnchor" id="H2130903462"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Symptom-based criteria have been proposed to standardize the diagnosis of functional dyspepsia. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rome IV criteria for functional dyspepsia</strong> – According to the Rome IV criteria, functional dyspepsia is defined as the presence of one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain or epigastric burning, and no evidence of structural disease (including at upper endoscopy) to explain the symptoms  (<a class="graphic graphic_table graphicRef108003" href="/z/d/graphic/108003.html" rel="external">table 1</a>) [<a href="#rid46">46</a>]. </p><p></p><p class="bulletIndent1">While patients with these symptoms and a negative diagnostic evaluation likely have functional dyspepsia, according to the Rome IV guidelines, the criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis. Criteria for symptom frequency and duration are particularly useful in defining patient eligibility for research, but clinician judgement may allow diagnosis in practice without rigid adherence to them. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional dyspepsia subtypes</strong> – Two subtypes of functional dyspepsia are recognized based on the predominant symptoms. However, overlap between these subtypes is common [<a href="#rid10">10,47</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postprandial distress syndrome is characterized by bothersome postprandial fullness and/or early satiation  (<a class="graphic graphic_table graphicRef108003" href="/z/d/graphic/108003.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epigastric pain syndrome is characterized by bothersome epigastric pain or burning that is not exclusively postprandial  (<a class="graphic graphic_table graphicRef108003" href="/z/d/graphic/108003.html" rel="external">table 1</a>). </p><p></p><p class="headingAnchor" id="H1031150335"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of functional dyspepsia includes other organic causes of dyspepsia  (<a class="graphic graphic_table graphicRef90590" href="/z/d/graphic/90590.html" rel="external">table 2</a>). Although there are several organic causes for dyspepsia, the main causes are peptic ulcer disease, gastritis, gastroesophageal reflux, and medications (eg, nonsteroidal anti-inflammatory drugs [NSAIDs]). An underlying gastric malignancy is a rare cause of dyspepsia in North America. Functional dyspepsia is differentiated from these by clinical assessment, laboratory testing, and upper endoscopy. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia", section on 'Dyspepsia secondary to organic disease'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux disease</strong> – The most common symptoms of gastroesophageal reflux disease are retrosternal burning pain and regurgitation. Dyspepsia symptoms can coexist with heartburn, but in patients with functional dyspepsia, epigastric pain, and fullness are the predominant symptoms [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroparesis</strong> – Gastroparesis is less prevalent than functional dyspepsia, but overlaps with it, as gastric emptying may be slow and symptoms of dyspepsia occur in both disorders [<a href="#rid49">49,50</a>]. Patients with functional dyspepsia may have nausea. However, in patients with gastroparesis, vomiting, rather than abdominal pain or epigastric fullness, is generally the predominant symptom. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritable bowel syndrome</strong> – More than 60 percent of patients with functional dyspepsia may have overlapping IBS symptoms [<a href="#rid8">8,46,51</a>], and the overlap may be more likely when the symptoms of either disorder are severe [<a href="#rid52">52</a>]. Rather than epigastric pain associated with functional dyspepsia, IBS is characterized by abdominal pain or discomfort associated with a change in stool form or frequency. As compared with patients with IBS alone, patients with both IBS and functional dyspepsia had increased bloating and abdominal pain after a lactulose-nutrient challenge test [<a href="#rid53">53</a>].  </p><p></p><p class="headingAnchor" id="H1585108645"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of patients with functional dyspepsia is controversial and alleviates symptoms in only a small proportion of patients  (<a class="graphic graphic_algorithm graphicRef115195" href="/z/d/graphic/115195.html" rel="external">algorithm 1</a>) [<a href="#rid46">46,54</a>]. </p><p class="headingAnchor" id="H293108854"><span class="h2">Initial approach</span><span class="headingEndMark"> — </span>Patients with functional dyspepsia should be tested and treated for <em>Helicobacter </em>pylori. We treat patients with functional dyspepsia who test negative for <em>H. pylori</em> and those with persistent symptoms four weeks after eradication of <em>H. pylori</em> with a proton pump inhibitor (PPI). A Cochrane systematic review revealed 14 patients needed to be treated to cure one case of dyspepsia [<a href="#rid17">17</a>]. (See <a class="local">'Helicobacter pylori test and treat'</a> below and <a class="local">'Proton pump inhibitors'</a> below and <a class="local">'Subsequent approach'</a> below.)</p><p class="headingAnchor" id="H1983809014"><span class="h3">Helicobacter pylori test and treat</span><span class="headingEndMark"> — </span>The diagnosis of <em>H. pylori</em> should be made with a test for active infection (stool antigen assay or urea breath test) if testing was not performed at the time of upper endoscopy performed for evaluation of dyspepsia  (<a class="graphic graphic_algorithm graphicRef115195" href="/z/d/graphic/115195.html" rel="external">algorithm 1</a>). Serologic testing should not be performed due to the low positive predictive value. (See  <a class="medical medical_review" href="/z/d/html/18.html" rel="external">"Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Approach to diagnostic testing'</a> and  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia", section on 'Diagnostic strategies and initial management'</a>.)</p><p><em>H. pylori</em> eradication may improve dyspeptic symptoms by altering acid secretion or modification of intestinal microbiota [<a href="#rid55">55,56</a>]. It also has the benefit of preventing unrecognized peptic ulcers associated with <em>H. pylori</em>. (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a> and <a class="local">'Epidemiology and pathophysiology'</a> above.)</p><p class="headingAnchor" id="H2578933246"><span class="h3">Proton pump inhibitors</span><span class="headingEndMark"> — </span>PPIs appear to be moderately effective in the treatment of some patients with functional dyspepsia. In a systematic review of 18 randomized controlled trials, PPIs were more effective than placebo in relieving overall dyspepsia symptoms (RR 0.88, 95% CI 0.82-0.94) with a NNT of 11 [<a href="#rid57">57</a>]. Low- and standard-dose PPIs had similar effectiveness. Twice daily PPI use has not been shown to be better than once daily use. PPIs may exert their beneficial effect by reducing duodenal eosinophils, mast cells, and mucosal permeability [<a href="#rid31">31</a>]. In patients with functional dyspepsia who respond to PPI therapy, attempts should be made to discontinue PPIs every 6 to 12 months to minimize long-term risk of therapy. </p><p class="headingAnchor" id="H2485648010"><span class="h3">H2-receptor antagonists</span><span class="headingEndMark"> — </span>In a meta-analysis of 12 trials with a total of 2183 patients, H2RAs were associated with a 23 percent reduction in symptoms compared with placebo (relative risk reduction [RRR] 23 percent, 95% CI 8-35 percent) with an NNT of 7 [<a href="#rid58">58</a>]. In the systematic review of PPI therapy for functional dyspepsia, only two studies compared the efficacy of PPIs with H2AAs, and no difference was evident [<a href="#rid57">57</a>]. However, the quality of most trials included was poor, and there was significant heterogeneity among studies. Another limitation of these studies is that patients with gastroesophageal reflux disease may have been misclassified as having functional dyspepsia. </p><p class="headingAnchor" id="H837817762"><span class="h2">Subsequent approach</span></p><p class="headingAnchor" id="H628516735"><span class="h3">Antidepressants</span><span class="headingEndMark"> — </span>In patients with functional dyspepsia whose symptoms do not improve after eight weeks of PPI therapy, we initiate a therapeutic trial with a tricyclic antidepressant (TCA). For patients with a partial clinical response to a PPI, a TCA can be initiated as combination therapy. For patients who fail to improve on a PPI, the PPI should be stopped and a TCA initiated. </p><p>We begin with a TCA at a low dose (eg, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> 10 mg, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> 10 mg, or <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> 25 mg at night). The dose may be increased at one- to two-week intervals. A dose of 20 to 30 mg is adequate in many patients, and we do not exceed a dose of 50 mg in most patients. Higher doses may not be more effective than lower doses and may be associated with daytime sedation and other anticholinergic side effects. We usually continue the TCA for 8 to 12 weeks before stopping, if it is ineffective. If the patient responds, we usually continue the drug for appropriately six months and then consider slowly tapering the medication off. The TCA can be resumed if dyspepsia recurs. While some clinicians prefer to use <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> rather than amitriptyline or desipramine, there are few clinical data to support its use. Low dose TCAs may also improve associated symptoms of insomnia and fibromyalgia in patients with functional dyspepsia [<a href="#rid59">59</a>].</p><p>The TCA <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> is beneficial for some patients. In a large trial, adequate relief was obtained by 53 percent of patients taking amitriptyline 50 mg once daily versus 40 percent of patients taking placebo [<a href="#rid60">60</a>]. A network meta-analysis revealed TCAs ranked second for efficacy (relative risk [RR] of remaining symptomatic 0.71, 95% CI 0.58-0.87) and first when only low risk of bias trials were included. Most of the trials that assessed TCAs studied patients who were refractory to other drugs analyzed in the network [<a href="#rid61">61</a>]. The drug did not delay gastric emptying and improved accommodation and postprandial bloating, but the exact mechanism of action remains unknown [<a href="#rid62">62</a>].</p><p><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> has also demonstrated benefit in patients with functional dyspepsia and unintentional weight loss that may be due to a central mechanism of action [<a href="#rid63">63-65</a>]. We usually begin with a low dose (eg, mirtazapine 7.5 mg one hour before bedtime) and slowly increase the dose; most patients need 30 to 45 mg daily. In 34 patients with &gt;10 percent weight loss randomized to mirtazapine 15 mg per day or placebo for eight weeks, mirtazapine reduced global symptoms of dyspepsia, early satiation, and gastrointestinal-specific anxiety. In addition, patients treated with mirtazapine reported improved nutrient tolerance and quality of life and weight gain [<a href="#rid63">63</a>]. In another study in which 60 patients with functional dyspepsia and &gt;5 percent weight loss randomized to mirtazapine 30 mg per day, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> 20 mg per day or conventional (acid inhibitor or prokinetic) therapy for eight weeks, mirtazapine reduced dyspepsia and depression and resulted in weight gain compared with the other two groups [<a href="#rid64">64</a>]. Mirtazapine-associated drowsiness was common in both studies. </p><p class="headingAnchor" id="H1380968936"><span class="h3">Prokinetic agents</span><span class="headingEndMark"> — </span>We reserve the use of prokinetics (eg, <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> 5 to 10 mg three times daily one-half an hour before meals and at night for four weeks), to patients in whom other therapies have failed and limit their duration to four weeks before discontinuing treatment [<a href="#rid8">8</a>]. If symptoms recur, we repeat a course of therapy, recognizing that up to 30 percent of patients may have side effects, most of which are generally mild and resolve with cessation of therapy [<a href="#rid8">8</a>]. </p><p>In a systematic review and meta-analysis that included 29 trials of six different prokinetics (<a class="drug drug_general" data-topicid="9269" href="/z/d/drug information/9269.html" rel="external">cisapride</a>, acotiamide, itopride, tegaserod, mosapride, and ABT-229) in patients with functional dyspepsia, overall, global symptom improvement was greater with prokinetics as compared with placebo (40 versus 26 percent, respectively) [<a href="#rid66">66</a>]. However, the quality of evidence to support the use of these agents was low. The use of prokinetics was not associated with an improvement in quality of life. All agents were well tolerated over a short term except cisapride. As few studies have related efficacy of treatment to gastric emptying, it has no role in directing therapy. Notably, no eligible studies assessed <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> or <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>, the only agents available in North America, in functional dyspepsia. Methodologic difficulties, including the frequent overlap of functional dyspepsia with gastroesophageal reflux disease, lack of validated endpoints, and presence of delayed gastric emptying in only a minority of patients [<a href="#rid13">13</a>] complicate designing studies of prokinetics [<a href="#rid67">67</a>]. </p><p>If postprandial nausea is a predominant symptom, trials of other antiemetic agents can be employed (eg, <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">promethazine</a>, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="9597" href="/z/d/drug information/9597.html" rel="external">meclizine</a>), although data from clinical trials are lacking. </p><p class="headingAnchor" id="H2456125740"><span class="h1">THERAPIES WITH LIMITED OR UNCLEAR ROLE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychotherapy</strong> – We reserve psychotherapy for motivated patients who associate symptoms with stressors and in patients who fail initial empiric medical therapy. The psychological factors associated with functional dyspepsia suggest that psychological therapy could help some patients. A systematic review of four trials (relaxation therapy and hypnosis, psychodrama, psychotherapy, and cognitive-behavioral therapy) suggested therapy could be beneficial for one year, but methodological deficiencies led to uncertainty about the results [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">"Overview of psychotherapies", section on 'Cognitive and behavioral therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fundic relaxant drugs</strong> – There is limited evidence that relaxing the gastric fundus may improve early satiation and postprandial fullness. In a small randomized trial, <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a> (10 mg, three times daily for four weeks) as compared with placebo increased gastric accommodation and reduced the overall severity of symptoms of dyspepsia, despite slowing gastric emptying of liquids [<a href="#rid69">69</a>]. In another study that included 32 patients with functional dyspepsia refractory to PPIs and/or <a class="drug drug_general" data-topicid="8777" href="/z/d/drug information/8777.html" rel="external">domperidone</a>, buspirone improved gastric emptying measured by <sup>13</sup>C-octanoic breath test and reduced early satiation [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antinociceptive</strong> <strong>agents</strong> – It is hypothesized that antinociceptive agents (eg, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">tramadol</a>, or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>) may impact the central processing of pain, thereby decreasing visceral hypersensitivity that has been associated with functional dyspepsia. A post hoc analysis of data obtained from six randomized controlled trials in patients with generalized anxiety disorder and prominent gastrointestinal symptoms showed that pregabalin was significantly more effective than placebo in treating both anxiety and gastrointestinal symptoms [<a href="#rid71">71</a>]. In a placebo-controlled trial of pregabalin in patients with irritable bowel syndrome reduced pain, but adequate relief did not differ from the placebo group [<a href="#rid72">72</a>]. However, results of trials in functional dyspepsia are needed. We do not routinely use of tramadol for the treatment of functional gastrointestinal disorders due to the potential for addiction. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complementary</strong> <strong>and</strong> <strong>alternative</strong> <strong>medicine</strong> – Several complementary and alternative medicine approaches to functional dyspepsia have been described. However, further studies are needed before they can be recommended [<a href="#rid73">73,74</a>]. A systematic review of several low quality studies involving herbal and natural products, acupuncture, and homeopathy suggested a benefit from peppermint oil and STW5, a European multiherbal preparation that includes peppermint and caraway [<a href="#rid75">75</a>]. STW5 may improve symptoms of functional dyspepsia by stimulating gastric fundic relaxation and antral motility [<a href="#rid76">76</a>]. An eight-week placebo-controlled trial of STW5 found statistically significant but marginal symptomatic improvement [<a href="#rid77">77</a>]. A study in 95 patients with FD (Rome III criteria) found that a combination of L-menthol and caraway oil improved postprandial FD symptoms in some patients [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary</strong> <strong>modification</strong> – The postprandial timing of symptoms suggests improvement could be obtained through dietary modification. However, a population case-control study failed to find an association between various foods and functional gastrointestinal disorders [<a href="#rid79">79</a>]. The multifactorial nature of functional dyspepsia and difficulty of conducting controlled dietary studies has markedly limited information useful to practice. Possibly, dieticians could help some patients through individualized approaches [<a href="#rid80">80</a>]. </p><p></p><p class="headingAnchor" id="H4209883975"><span class="h1">ADDITIONAL EVALUATION OF PERSISTENT SYMPTOMS</span><span class="headingEndMark"> — </span>Patients with functional dyspepsia who have persistent symptoms of dyspepsia may require additional testing for an alternate diagnosis. We perform a gastric emptying study to evaluate for gastroparesis in selected patients with refractory functional dyspepsia who have persistent nausea and vomiting or risk factors for delayed gastric emptying (eg, diabetes mellitus). However, it is important that a significant overlap exists between dyspepsia and gastroparesis [<a href="#rid49">49,50</a>]; and treatment directed at accelerating delayed gastric emptying in these patients may not necessarily improve symptoms. (See  <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">"Treatment of gastroparesis"</a>.)</p><p class="headingAnchor" id="H3857289424"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Functional dyspepsia has a chronic disease course with symptoms that vary in severity over time [<a href="#rid51">51</a>]. Patients may be asymptomatic for periods of time and have periodic symptomatic relapses. In two population-based studies of the natural history of functional dyspepsia, over a follow-up of 10 to 12 years approximately 15 to 20 percent of individuals had persistent symptoms and 40 to 52 percent had symptom resolution [<a href="#rid81">81</a>]. In 30 to 35 percent of patients symptoms fluctuated over time and patients met criteria for another functional gastrointestinal disorder.</p><p><strong>SOCIETY GUIDELINE LINKS</strong> — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118346.html" rel="external">"Society guideline links: Dyspepsia"</a>.)</p><p class="headingAnchor" id="H4038675283"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15388.html" rel="external">"Patient education: Stomach ache and stomach upset (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2009.html" rel="external">"Patient education: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2578852124"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of functional dyspepsia is up to 20 percent worldwide. The pathophysiology of functional dyspepsia is not well understood. Several potential mechanisms have been suggested. (See <a class="local">'Epidemiology and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with functional dyspepsia describe postprandial fullness, early satiety, and/or epigastric pain/ burning. Nausea, vomiting, or heartburn are less frequent. (See <a class="local">'Epidemiology and pathophysiology'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical diagnosis of functional dyspepsia requires the fulfillment of symptom-based diagnostic criteria and an evaluation to exclude other causes of dyspepsia  (<a class="graphic graphic_algorithm graphicRef115195" href="/z/d/graphic/115195.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef108003" href="/z/d/graphic/108003.html" rel="external">table 1</a>). This evaluation consists of a history, physical examination, laboratory studies, and endoscopic evaluation to exclude organic/structural disease underlying the symptoms. The evaluation of a patient with dyspepsia to establish the cause is discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non-invasive testing for active <em>Helicobacter pylori (H. pylori</em>) infection should be performed in patients with functional dyspepsia if gastric biopsies were not obtained for <em>H. pylori</em> on upper endoscopy  (<a class="graphic graphic_algorithm graphicRef115195" href="/z/d/graphic/115195.html" rel="external">algorithm 1</a>). We suggest treatment for <em>H. pylori</em> in patients with functional dyspepsia who test positive for an infection (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). (See  <a class="medical medical_review" href="/z/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest a four- to eight-week trial of a once daily proton pump inhibitor (PPI) in patients with functional dyspepsia and no evidence of <em>H. pylori</em> and patients with persistent symptoms after eradication of <em>H. pylori</em> (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). (See <a class="local">'Proton pump inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest a tricyclic antidepressant drug for patients with persistent symptoms after an eight-week trial of a PPI (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We start with a low dose (eg, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> 10 mg at bedtime, <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> 10 mg at bedtime, or <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a> 25 mg at bedtime) and gradually increase the dose as tolerated. (See <a class="local">'Antidepressants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest the use of prokinetics in patients in whom eradication of <em>H. pylori </em>and a trial of proton pump inhibitor and tricyclic antidepressant has failed (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In such patients, we generally limit a trial of <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> to 5 to 10 mg three times daily one-half an hour before meals and at night for about four weeks. The risk of side effects, including tardive dyskinesia, increase with the cumulative dose and duration of treatment. We refer motivated patients who fail medical therapy and patients who associate symptoms with stressors for psychotherapy. (See <a class="local">'Prokinetic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional dyspepsia has a chronic disease course with symptoms that vary in severity over time. Patients may be asymptomatic for periods of time followed by symptomatic relapses. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet 2020; 396:1689.</a></li><li><a class="nounderline abstract_t">Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015; 64:1049.</a></li><li><a class="nounderline abstract_t">Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol 2018; 3:252.</a></li><li><a class="nounderline abstract_t">Hantoro IF, Syam AF, Mudjaddid E, et al. Factors associated with health-related quality of life in patients with functional dyspepsia. Health Qual Life Outcomes 2018; 16:83.</a></li><li><a class="nounderline abstract_t">Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001; 96:1340.</a></li><li><a class="nounderline abstract_t">Drossman DA, Tack J, Ford AC, et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology 2018; 154:1140.</a></li><li><a class="nounderline abstract_t">Talley NJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129:1753.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112:988.</a></li><li><a class="nounderline abstract_t">Wauters L, Dickman R, Drug V, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J 2021; 9:307.</a></li><li><a class="nounderline abstract_t">Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Am J Gastroenterol 2017; 112:132.</a></li><li><a class="nounderline abstract_t">Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130:296.</a></li><li><a class="nounderline abstract_t">Ly HG, Weltens N, Tack J, Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. Clin Gastroenterol Hepatol 2015; 13:1584.</a></li><li><a class="nounderline abstract_t">Park SY, Acosta A, Camilleri M, et al. Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms. Am J Gastroenterol 2017; 112:1689.</a></li><li><a class="nounderline abstract_t">Farré R, Vanheel H, Vanuytsel T, et al. In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. Gastroenterology 2013; 145:566.</a></li><li><a class="nounderline abstract_t">Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010; 105:913.</a></li><li><a class="nounderline abstract_t">Bharucha AE, Camilleri M, Burton DD, et al. Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia. Am J Gastroenterol 2014; 109:1910.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002096.</a></li><li><a class="nounderline abstract_t">Mearin F, Pérez-Oliveras M, Perelló A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129:98.</a></li><li><a class="nounderline abstract_t">Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010; 138:1727.</a></li><li><a class="nounderline abstract_t">Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108:1558.</a></li><li><a class="nounderline abstract_t">Rahman MM, Ghoshal UC, Sultana S, et al. Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study. Am J Gastroenterol 2018; 113:1363.</a></li><li><a class="nounderline abstract_t">Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". Arch Intern Med 2011; 171:1936.</a></li><li><a class="nounderline abstract_t">Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut 2017; 66:1168.</a></li><li><a class="nounderline abstract_t">Gargala G, Lecleire S, François A, et al. Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia. World J Gastroenterol 2007; 13:2333.</a></li><li><a class="nounderline abstract_t">Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106:1089.</a></li><li><a class="nounderline abstract_t">Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1175.</a></li><li><a class="nounderline abstract_t">Vanheel H, Vicario M, Boesmans W, et al. Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation. Sci Rep 2018; 8:5383.</a></li><li><a class="nounderline abstract_t">Du L, Shen J, Kim JJ, et al. Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study. Sci Rep 2016; 6:34305.</a></li><li><a class="nounderline abstract_t">Cirillo C, Bessissow T, Desmet AS, et al. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol 2015; 110:1205.</a></li><li><a class="nounderline abstract_t">Nojkov B, Zhou SY, Dolan RD, et al. Evidence of Duodenal Epithelial Barrier Impairment and Increased Pyroptosis in Patients With Functional Dyspepsia on Confocal Laser Endomicroscopy and "Ex Vivo" Mucosa Analysis. Am J Gastroenterol 2020; 115:1891.</a></li><li><a class="nounderline abstract_t">Wauters L, Ceulemans M, Frings D, et al. Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. Gastroenterology 2021; 160:1521.</a></li><li><a class="nounderline abstract_t">Tack J, Schol J, Van den Houte K, et al. Paradigm Shift: Functional Dyspepsia-A "Leaky Gut" Disorder? Am J Gastroenterol 2021; 116:274.</a></li><li><a class="nounderline abstract_t">Vanner S, Greenwood-Van Meerveld B, Mawe G, et al. Fundamentals of Neurogastroenterology: Basic Science. Gastroenterology 2016.</a></li><li><a class="nounderline abstract_t">Vanuytsel T, van Wanrooy S, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014; 63:1293.</a></li><li><a class="nounderline abstract_t">Chen Y, Wang R, Hou B, et al. Regional Brain Activity During Rest and Gastric Water Load in Subtypes of Functional Dyspepsia: A Preliminary Brain Functional Magnetic Resonance Imaging Study. J Neurogastroenterol Motil 2018; 24:268.</a></li><li><a class="nounderline abstract_t">Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2:985.</a></li><li><a class="nounderline abstract_t">Mak AD, Wu JC, Chan Y, et al. Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study. Aliment Pharmacol Ther 2012; 36:800.</a></li><li><a class="nounderline abstract_t">Koloski NA, Jones M, Kalantar J, et al. The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61:1284.</a></li><li><a class="nounderline abstract_t">Drossman DA, Talley NJ, Leserman J, et al. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995; 123:782.</a></li><li><a class="nounderline abstract_t">Dibaise JK, Islam RS, Dueck AC, et al. Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying. Neurogastroenterol Motil 2016; 28:196.</a></li><li><a class="nounderline abstract_t">Longstreth GF. Relation between physical or sexual abuse and functional gastrointestinal disorders. Perm J 1998; 2:9.</a></li><li><a class="nounderline abstract_t">Videlock EJ, Adeyemo M, Licudine A, et al. Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. Gastroenterology 2009; 137:1954.</a></li><li><a class="nounderline abstract_t">Kindt S, Van Oudenhove L, Mispelon L, et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol 2011; 106:340.</a></li><li><a class="nounderline abstract_t">Barberio B, Pinto-Sanchez MI, Bercik P, et al. Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. Aliment Pharmacol Ther 2021; 53:253.</a></li><li><a class="nounderline abstract_t">Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57:1495.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology 2016; 150:1380.</a></li><li><a class="nounderline abstract_t">Carbone F, Holvoet L, Tack J. Rome III functional dyspepsia subdivision in PDS and EPS: recognizing postprandial symptoms reduces overlap. Neurogastroenterol Motil 2015; 27:1069.</a></li><li><a class="nounderline abstract_t">Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol 2013; 10:175.</a></li><li><a class="nounderline abstract_t">Lacy BE. Functional dyspepsia and gastroparesis: one disease or two? Am J Gastroenterol 2012; 107:1615.</a></li><li><a class="nounderline abstract_t">Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 2014; 63:1972.</a></li><li><a class="nounderline abstract_t">Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med 2015; 373:1853.</a></li><li><a class="nounderline abstract_t">von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2019; 64:480.</a></li><li><a class="nounderline abstract_t">Pohl D, Van Oudenhove L, Törnblom H, et al. Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2018; 16:1745.</a></li><li><a class="nounderline abstract_t">Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Deeks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98:2621.</a></li><li><a class="nounderline abstract_t">Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171:1929.</a></li><li><a class="nounderline abstract_t">Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017; 11:CD011194.</a></li><li><a class="nounderline abstract_t">Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; :CD001960.</a></li><li><a class="nounderline abstract_t">Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65.</a></li><li><a class="nounderline abstract_t">Talley NJ, Locke GR, Saito YA, et al. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology 2015; 149:340.</a></li><li><a class="nounderline abstract_t">Ford AC, Moayyedi P, Black CJ, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther 2021; 53:8.</a></li><li><a class="nounderline abstract_t">Lacy BE, Saito YA, Camilleri M, et al. Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia. Am J Gastroenterol 2018; 113:216.</a></li><li><a class="nounderline abstract_t">Tack J, Ly HG, Carbone F, et al. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. Clin Gastroenterol Hepatol 2016; 14:385.</a></li><li><a class="nounderline abstract_t">Jiang SM, Jia L, Liu J, et al. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol 2016; 22:5260.</a></li><li><a class="nounderline abstract_t">Carbone F, Vanuytsel T, Tack J. The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects. Neurogastroenterol Motil 2017; 29.</a></li><li><a class="nounderline abstract_t">Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol 2019; 114:233.</a></li><li><a class="nounderline abstract_t">Tack J, Van den Houte K, Carbone F. The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome. Am J Gastroenterol 2019; 114:204.</a></li><li><a class="nounderline abstract_t">Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002301.</a></li><li><a class="nounderline abstract_t">Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10:1239.</a></li><li><a class="nounderline abstract_t">Caviglia GP, Sguazzini C, Cisarò F, et al. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. Minerva Med 2017; 108:489.</a></li><li><a class="nounderline abstract_t">Stein DJ, Bruce Lydiard R, Herman BK, Mandel FS. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009; 24:126.</a></li><li><a class="nounderline abstract_t">Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019; 49:389.</a></li><li><a class="nounderline abstract_t">Gan Y, Liu H, Yang L, Yang K. Effect of banxiaxiexin tang on treatment of functional dyspepsia: a meta-analysis of randomized controlled trials. J Tradit Chin Med 2014; 34:140.</a></li><li><a class="nounderline abstract_t">Lan L, Zeng F, Liu GJ, et al. Acupuncture for functional dyspepsia. Cochrane Database Syst Rev 2014; :CD008487.</a></li><li><a class="nounderline abstract_t">Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004; 2:957.</a></li><li><a class="nounderline abstract_t">Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276.</a></li><li><a class="nounderline abstract_t">von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268.</a></li><li><a class="nounderline abstract_t">Chey WD, Lacy BE, Cash BD, et al. A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial. Clin Transl Gastroenterol 2019; 10:e00021.</a></li><li><a class="nounderline abstract_t">Saito YA, Locke GR 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100:2743.</a></li><li><a class="nounderline abstract_t">Duncanson K, Burns G, Pryor J, et al. Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis 2012; 44:211.</a></li></ol></div><div id="topicVersionRevision">Topic 19 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33049222" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147201" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396034" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29720190" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Factors associated with health-related quality of life in patients with functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11374666" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29274869" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16285970" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : American Gastroenterological Association medical position statement: evaluation of dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28631728" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ACG and CAG Clinical Guideline: Management of Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939891" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27958284" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16472585" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25869636" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895582" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23702005" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160711" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403365" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674892" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Eradication of Helicobacter pylori for non-ulcer dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16012939" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20117111" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23711623" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171215" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123803" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489239" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dyspepsia and the microbiome: time to focus on the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17511033" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245834" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686660" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29599471" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708358" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077177" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33156108" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evidence of Duodenal Epithelial Barrier Impairment and Increased Pyroptosis in Patients With Functional Dyspepsia on Confocal Laser Endomicroscopy and "Ex Vivo" Mucosa Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346007" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33298703" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Paradigm Shift: Functional Dyspepsia-A "Leaky Gut" Disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144618" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fundamentals of Neurogastroenterology: Basic Science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24153250" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605982" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Regional Brain Activity During Rest and Gastric Water Load in Subtypes of Functional Dyspepsia: A Preliminary Brain Functional Magnetic Resonance Imaging Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551251" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22957985" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234979" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574197" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sexual and physical abuse and gastrointestinal illness. Review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26511077" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Relation between physical or sexual abuse and functional gastrointestinal disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737564" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978482" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280149" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519430" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Relationship between symptoms and ingestion of a meal in functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27147122" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gastroduodenal Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220647" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rome III functional dyspepsia subdivision in PDS and EPS: recognizing postprandial symptoms reduces overlap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23296247" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Overlap of functional dyspepsia and GERD--diagnostic and treatment implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160285" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Functional dyspepsia and gastroparesis: one disease or two?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25260920" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gastroparesis: separate entity or just a part of dyspepsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535514" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Functional Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30368683" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702295" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591037" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Review article: current treatment options and management of functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687807" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123802" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Helicobacter pylori eradication in functional dyspepsia: HEROES trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29161458" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Proton pump inhibitors for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054151" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pharmacological interventions for non-ulcer dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11059442" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25921377" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32936964" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29257140" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538208" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27298569" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28695632" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337705" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730856" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846636" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Psychological interventions for non-ulcer dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813445" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28707862" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19352198" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30663077" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24783922" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of banxiaxiexin tang on treatment of functional dyspepsia: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25306866" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acupuncture for functional dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551247" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378904" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531013" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30939487" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16393229" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Diet and functional gastrointestinal disorders: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33800668" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137573" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
